La lista delle pubblicazioni scientifiche che mi vedono come autore
2024. SANI clinical remission definition: a useful tool in severe asthma management.  J Asthma. 2024. Editorial: pharmacotherapy and evidence-based medicine.  Curr Opin Allergy Clin Immunol 24(4):228-229 2024. New evidence in food allergies treatment.  Curr Opin Allergy Clin Immunol 24(4):251-256 2024. Clinical remission in severe asthma: lights and shadows on an ambitious goal.  Curr Opin Allergy Clin Immunol 24(4):230-236 2024. Asthma management, focused on the use of oral corticosteroids: the opinions of Italian asthmatic patients.  J Asthma. 2024. Meta-analysis in allergy-Statistical recommendations.  Allergy 79(6):1616-1618 2024. IR (index of reactivity)-house dust mite sublingual immunotherapy liquid formulation for allergic rhinoconjunctivitis: Systematic review and meta-analysis of randomized and nonrandomized studies.  J Allergy Clin Immunol Glob 3(2):100208 2024. Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?  Int J Mol Sci 25. 2024. Radiological Versus Clinical 1-Year Outcomes of Dupilumab in Refractory CRSwNP: A Real-Life Study.  Laryngoscope 134(6):2626-2633 2024. Statistical advice provided by ChatGPT regarding an accepted article in Allergy.  Allergy 79(3):748-751 2024. Sleep quality burden in chronic rhinosinusitis with nasal polyps and its modulation by dupilumab.  Ann Allergy Asthma Immunol 132(1):69-75 2023. Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.  Biomedicines 11. 2023. Editorial comment on "Environmental influences on childhood asthma: Climate change".  Pediatr Allergy Immunol 34(8):e14011 2023. Impulse oscillometry defined small airway dysfunction in asthmatic patients with normal spirometry: Prevalence, clinical associations, and impact on asthma control.  Respir Med 218:107391 2023. Advancing precision medicine in asthma: Evolution of treatment outcomes.  J Allergy Clin Immunol 152(4):835-840 2023. Editorial: pharmacotherapy and evidence-based medicine section.  Curr Opin Allergy Clin Immunol 23(4):307-308 2023. Real-world data: A relevant component in the framework of scientific evidence.  Asia Pac Allergy 13(1):40-43 2023. COPD and biologic treatment: state of the art.  Curr Opin Allergy Clin Immunol 23(4):309-318 2023. Mast Cells in Upper and Lower Airway Diseases: Sentinels in the Front Line.  Int J Mol Sci 24. 2023. Polyethylene Glycol and Polysorbate 80 Skin Tests in the Context of an Allergic Risk Assessment for Hypersensitivity Reactions to Anti-SARS-CoV-2 mRNA Vaccines.  Vaccines (Basel) 11. 2023. Desensitization Protocols for Anti-SARS-CoV-2 Vaccines in Patients with High Risk of Allergic Reactions.  Vaccines (Basel) 11. 2023. The Prevalence of Immediate Hypersensitivity Reactions to the BNT162b2 mRNA Vaccine against SARS-CoV-2: Data from the Vaccination Campaign in a Large Academic Hospital.  Vaccines (Basel) 11. 2023. Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation.  J Pers Med 13. 2023. Oral Corticosteroid Abuse and Self-Prescription in Italy: A Perspective from Community Pharmacists and Sales Reports before and during the COVID-19 Era.  J Pers Med 13. 2023. Evolution in Endoscopic Sinus Surgery: The Adjuvant Role of Reboot Surgery in Patients with Uncontrolled Nasal Symptoms of Eosinophilic Granulomatosis with Polyangiitis.  J Pers Med 13. 2023. Care for Patients with Type-2 Chronic Rhinosinusitis.  J Pers Med 13. 2023. Use, Abuse, and Misuse of Nasal Medications: Real-Life Survey on Community Pharmacist's Perceptions.  J Pers Med 13. 2023. Intranasal corticosteroid and antihistamine combinations in the treatment of allergic rhinitis: the role of the novel formulation olopatadine/mometasone furoate.  Expert Rev Clin Immunol 19(6):575-584 2023. Comparison of evidence of treatment effects in randomized and nonrandomized studies on allergen immunotherapy.  Clin Exp Allergy 53(6):610-625 2023. Exhaled nitric oxide in asthma: from diagnosis to management.  Curr Opin Allergy Clin Immunol 23(1):29-35 2023. Local Allergic Rhinitis: Lights and Shadows of a Mysterious Entity.  Int Arch Allergy Immunol 184(1):12-20 2023. Outcomes of Non-Mucosa Sparing Endoscopic Sinus Surgery (Partial Reboot) in Refractory Chronic Rhinosinusitis with Nasal Polyposis: An Academic Hospital Experience.  Laryngoscope 133(7):1584-1589 2023. Middle meatus nasal cytology compared to inferior turbinate cytology in non allergic rhinitis.  Eur Arch Otorhinolaryngol 280(2):913-918 2022. Cross-Cultural Validation of the Short Version of the Questionnaire of Olfactory Disorders-Negative Statements into Italian: Towards Personalized Patient Care.  J Pers Med 12. 2022. Nasal cytology as a reliable non-invasive procedure to phenotype patients with type 2 chronic rhinosinusitis with nasal polyps.  World Allergy Organ J 15(11):100700 2022. Critical evaluation of asthma biomarkers in clinical practice.  Front Med (Lausanne) 9:969243 2022. Biologics and airway remodeling in severe asthma.  Allergy 77(12):3538-3552 2022. Current treatment strategies for seasonal allergic rhinitis: where are we heading?  Clin Mol Allergy 20(1):9 2022. Editorial: Pharmacotherapy and evidence based medicine.  Curr Opin Allergy Clin Immunol 22(4):257-258 2022. Severe asthma and personalized approach in the choice of biologic.  Curr Opin Allergy Clin Immunol 22(4):268-275 2022. Prevalence of familial link in patients affected by chronic rhinosinusitis with nasal polyposis.  Int Forum Allergy Rhinol 12(12):1562-1565 2022. Artificial intelligence processing electronic health records to identify commonalities and comorbidities cluster at Immuno Center Humanitas.  Clin Transl Allergy 12(6):e12144 2022. Biologics in severe asthma: the role of real-world evidence from registries.  Eur Respir Rev 31. 2022. New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine.  Vaccines (Basel) 10. 2022. The Present and Future of Allergen Immunotherapy in Personalized Medicine.  J Pers Med 12. 2022. Nasal Polyposis Quality of Life (NPQ): Development and Validation of the First Specific Quality of Life Questionnaire for Chronic Rhinosinusitis with Nasal Polyps.  Healthcare (Basel) 10. 2022. Impact of asthma on bronchiectasis severity and risk of exacerbations.  J Asthma 59(3):469-475 2021. Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.  Front Physiol 12:815842 2021. Allergen immunotherapy for respiratory allergy: Quality appraisal of observational comparative effectiveness studies using the REal Life Evidence AssessmeNt Tool. An EAACI methodology committee analysis.  Clin Transl Allergy 11(4):e12033 2021. Diagnostic delay and misdiagnosis in eosinophilic oesophagitis.  Dig Liver Dis 53(12):1632-1639 2021. Successful SARS-CoV-2 vaccine allergy risk-management: The experience of a large Italian University Hospital.  World Allergy Organ J 14(5):100541 2021. Reply to: Kow CS et al. Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?  Allergy 76(3):961-962 2021. Allergen immunotherapy: The growing role of observational and randomized trial "Real-World Evidence".  Allergy 76(9):2663-2672 2021. Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI.  Allergy Asthma Immunol Res 13(2):219-228 2021. Community pharmacist's professional adaptation amid Covid-19 emergency: a national survey on Italian pharmacists.  Int J Clin Pharm 43(3):708-715 2021. Gastroesophageal reflux and asthma: when, how, and why.  Curr Opin Allergy Clin Immunol 21(1):52-58 2021. Allergen immunotherapy and biologics in respiratory allergy: friends or foes?  Curr Opin Allergy Clin Immunol 21(1):16-23 2021. Alpha1-antitrypsin deficiency and asthma.  Curr Opin Allergy Clin Immunol 21(1):46-51 2021. Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry.  Expert Rev Respir Med 15(3):419-424 2021. COVID-19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments.  Allergy 76(3):887-892 2020. Effect of an educational intervention delivered by pharmacists on adherence to treatment, disease control and lung function in patients with asthma.  Respir Med 174:106199 2020. Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma.  J Breath Res 15(1):016007 2020. Clinical presentation at the onset of COVID-19 and allergic rhinoconjunctivitis.  J Allergy Clin Immunol Pract 8(10):3587-3589 2020. Allergy clinics in times of the SARS-CoV-2 pandemic: an integrated model.  Clin Transl Allergy 10:23 2020. Do the current guidelines for asthma pharmacotherapy encourage over-treatment?  Expert Opin Pharmacother 21(11):1283-1286 2020. An academic allergy unit during COVID-19 pandemic in Italy.  J Allergy Clin Immunol 146(1):227 2020. Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).  Multidiscip Respir Med 15(1):36 2020. Vaping effects on asthma: results from a web survey and clinical investigation.  Intern Emerg Med 15(4):663-671 2020. The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life.  Allergy 75(6):1460-1463 2019. Interleukin-5 in the Pathophysiology of Severe Asthma.  Front Physiol 10:1514 2019. Immunostimulants in respiratory diseases: focus on Pidotimod.  Multidiscip Respir Med 14:31 2019. One year of mepolizumab. Efficacy and safety in real-life in Italy.  Pulm Pharmacol Ther 58:101836 2019. Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients.  Eur J Intern Med 68:e7-e11 2019. Real-life studies of biologics used in asthma patients: key differences and similarities to trials.  Expert Rev Clin Immunol 15(9):951-958 2019. Asthma from immune pathogenesis to precision medicine.  Semin Immunol 46:101294 2019. Treatable traits in chronic rhinosinusitis with nasal polyps.  Curr Opin Allergy Clin Immunol 19(4):373-378 2019. New drugs in early-stage clinical trials for allergic rhinitis.  Expert Opin Investig Drugs 28(3):267-273 Publication list retrieved from NCBI using ImpactPubs